Log in

NYSE:ZYME - Zymeworks Stock Price, Forecast & News

$39.66
-2.17 (-5.19 %)
(As of 12/10/2019 08:12 AM ET)
Today's Range
$38.96
Now: $39.66
$41.83
50-Day Range
$29.62
MA: $37.11
$44.08
52-Week Range
$10.72
Now: $39.66
$45.58
Volume260,055 shs
Average Volume334,550 shs
Market Capitalization$1.56 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.53
Zymeworks Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The company's lead product candidates include ZW25, a bispecific antibody that is in Phase I clinical trial for the treatment of breast and gastric cancer; ZW49, a bispecific antibody-drug conjugate that is in preclinical stage for treating breast and gastric cancers, and solid tumors. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Previous SymbolNASDAQ:ZYME
CUSIPN/A
Phone604-678-1388

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$53.02 million
Book Value$5.64 per share

Profitability

Net Income$-36,560,000.00
Net Margins-112.95%

Miscellaneous

Employees180
Market Cap$1.56 billion
Next Earnings Date3/4/2020 (Estimated)
OptionableOptionable

Receive ZYME News and Ratings via Email

Sign-up to receive the latest news and ratings for ZYME and its competitors with MarketBeat's FREE daily newsletter.


Zymeworks (NYSE:ZYME) Frequently Asked Questions

What is Zymeworks' stock symbol?

Zymeworks trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZYME."

How were Zymeworks' earnings last quarter?

Zymeworks Inc (NYSE:ZYME) released its earnings results on Tuesday, November, 5th. The company reported ($0.70) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.76) by $0.06. The company had revenue of $7.86 million for the quarter, compared to analysts' expectations of $7.77 million. Zymeworks had a negative return on equity of 25.72% and a negative net margin of 112.95%. View Zymeworks' Earnings History.

When is Zymeworks' next earnings date?

Zymeworks is scheduled to release their next quarterly earnings announcement on Wednesday, March 4th 2020. View Earnings Estimates for Zymeworks.

What price target have analysts set for ZYME?

10 brokers have issued 12 month price objectives for Zymeworks' stock. Their forecasts range from $23.00 to $65.00. On average, they expect Zymeworks' share price to reach $43.20 in the next year. This suggests a possible upside of 8.9% from the stock's current price. View Analyst Price Targets for Zymeworks.

What is the consensus analysts' recommendation for Zymeworks?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zymeworks in the last year. There are currently 2 hold ratings, 7 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Zymeworks.

Has Zymeworks been receiving favorable news coverage?

Media headlines about ZYME stock have been trending somewhat negative recently, InfoTrie Sentiment reports. The research firm rates the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Zymeworks earned a media sentiment score of -1.2 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the immediate future. View News Stories for Zymeworks.

Are investors shorting Zymeworks?

Zymeworks saw a decrease in short interest in the month of November. As of November 15th, there was short interest totalling 458,700 shares, a decrease of 21.5% from the October 31st total of 584,400 shares. Based on an average daily volume of 290,000 shares, the short-interest ratio is presently 1.6 days. Approximately 1.5% of the shares of the company are sold short. View Zymeworks' Current Options Chain.

Who are some of Zymeworks' key competitors?

What other stocks do shareholders of Zymeworks own?

Who are Zymeworks' key executives?

Zymeworks' management team includes the folowing people:
  • Dr. Ali Tehrani, Co-Founder, Pres, CEO & Director (Age 47)
  • Mr. Neil A. Klompas C.A., CPA, CPA, CA, Chief Financial Officer (Age 47)
  • Dr. Anthony J. Polverino, Chief Scientific Officer & Exec. VP of Early Devel. (Age 56)
  • Dr. Diana F. Hausman, Chief Medical Officer (Age 56)
  • Dr. Surjit Dixit, VP of Technology (Age 46)

When did Zymeworks IPO?

(ZYME) raised $65 million in an initial public offering (IPO) on Friday, April 28th 2017. The company issued 4,500,000 shares at a price of $13.00-$16.00 per share. Citigroup, Barclays, Wells Fargo Securities and Canaccord Genuity served as the underwriters for the IPO and Cormark Securities was co-manager.

Who are Zymeworks' major shareholders?

Zymeworks' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Great Point Partners LLC (6.26%), Millennium Management LLC (3.50%), Pictet Asset Management Ltd. (1.21%), California Public Employees Retirement System (0.17%), Stifel Financial Corp (0.12%) and State Street Corp (0.03%). Company insiders that own Zymeworks stock include Ali Tehrani, David Kai Yuen Poon, Eli & Co Lilly and Neil A Klompas. View Institutional Ownership Trends for Zymeworks.

Which institutional investors are selling Zymeworks stock?

ZYME stock was sold by a variety of institutional investors in the last quarter, including K.J. Harrison & Partners Inc, State of Tennessee Treasury Department and SG Americas Securities LLC. Company insiders that have sold Zymeworks company stock in the last year include Ali Tehrani, David Kai Yuen Poon, Eli & Co Lilly and Neil A Klompas. View Insider Buying and Selling for Zymeworks.

Which institutional investors are buying Zymeworks stock?

ZYME stock was acquired by a variety of institutional investors in the last quarter, including Great Point Partners LLC, Millennium Management LLC, Pictet Asset Management Ltd., Stifel Financial Corp, State Street Corp, California Public Employees Retirement System, Cutler Group LP and HWG Holdings LP. View Insider Buying and Selling for Zymeworks.

How do I buy shares of Zymeworks?

Shares of ZYME can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Zymeworks' stock price today?

One share of ZYME stock can currently be purchased for approximately $39.66.

How big of a company is Zymeworks?

Zymeworks has a market capitalization of $1.56 billion and generates $53.02 million in revenue each year. The company earns $-36,560,000.00 in net income (profit) each year or ($1.26) on an earnings per share basis. Zymeworks employs 180 workers across the globe.View Additional Information About Zymeworks.

What is Zymeworks' official website?

The official website for Zymeworks is http://www.zymeworks.com/.

How can I contact Zymeworks?

Zymeworks' mailing address is 540-1385 WEST 8TH AVENUE, Vancouver A1, V6H 3V9. The company can be reached via phone at 604-678-1388 or via email at [email protected]


MarketBeat Community Rating for Zymeworks (NYSE ZYME)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  202 (Vote Outperform)
Underperform Votes:  164 (Vote Underperform)
Total Votes:  366
MarketBeat's community ratings are surveys of what our community members think about Zymeworks and other stocks. Vote "Outperform" if you believe ZYME will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZYME will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/10/2019 by MarketBeat.com Staff

Featured Article: Forex

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel